| Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity 2009 · fish-oil intervention group · Adults with metabolic syndrome; mean age 52.9 years; sex not specified | 120 mg | 1 g | 26 weeks | 60 |
| Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial 2012 · n-3 LCPUFA group · Pregnant women from Adelaide whose unborn baby had a mother, father, or sibling with a history of medically diagnosed allergic disease | 800 mg | 1.5 g | — | 368 |
| An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults 2020 · FO group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression | 400 mg | 2 g | 16 weeks | 31 |
| An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults 2020 · FO + CUR group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression | 400 mg | 2 g | 16 weeks | 30 |
| Prenatal Fish Oil Supplementation and Allergy: 6-Year Follow-up of a Randomized Controlled Trial 2016 · n-3 LCPUFA-rich fish oil capsules · Pregnant women with a family history of allergic disease | 800 mg | — | — | 367 |
| Effects of Varied Omega-3 Fatty Acid Supplementation on Postpartum Mental Health and the Association between Prenatal Erythrocyte Omega-3 Fatty Acid Levels and Postpartum Mental Health 2023 · fish oil group · Healthy primiparous pregnant women aged 19–45 years | 400 mg | 5.2 g | 12 weeks | 124 |
| Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development 2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required | 200 mg | 2 mL | 26 weeks | 87 |
| Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children 2023 · Fish oil + placebo · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated | 3.8 g | 4.8 g | — | 82 |
| Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children 2023 · Probiotics + fish oil · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated | 3.8 g | 4.8 g | — | 82 |
| The effect of perinatal fish oil supplementation on neurodevelopment and growth of infants: a randomized controlled trial 2018 · fish oil supplementation group · Pregnant women aged 18–35 years | 120 mg | — | — | 75 |
| Long-Chain Polyunsaturated Fatty Acids, Homocysteine at Birth and Fatty Acid Desaturase Gene Cluster Polymorphisms are Associated with Children's Processing Speed up to Age 9 Years 2020 · FO · Healthy pregnant women; offspring were assessed at 7.5 and 9 years | 500 mg | 150 mg | — | 38 |
| Long-Chain Polyunsaturated Fatty Acids, Homocysteine at Birth and Fatty Acid Desaturase Gene Cluster Polymorphisms are Associated with Children's Processing Speed up to Age 9 Years 2020 · FO + 5-MTHF · Healthy pregnant women; offspring were assessed at 7.5 and 9 years | 500 mg | 150 mg | — | 36 |
| Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial 2008 · fish oil group · Pregnant women receiving supplementation from 20 weeks’ gestation until delivery; their children were assessed at age 2.5 years | 2.2 g | — | — | 33 |
| Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome 2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation | 71.9 mg/kg | 10 mL | 1 year | 33 |
| Effect of Docosahexaenoic Acid and Eicosapentaenoic Acid Supplementation on Sleep Quality in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial 2022 · DHA/EPA supplementation group · Healthy Japanese adults aged 45 years or older with poor sleep quality; male and female | 576 mg | 2.88 g | 12 weeks | 33 |
| Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial 2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day | 600 mg | 5 g | 90 days | 27 |
| Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial 2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder | 780 mg | 1.35 g | 12 weeks | 27 |
| The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial 2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery | 780 mg | 2 g | 30 days | 18 |
| Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial 2013 · fish oil group · People with dry eye syndrome | 540 mg | 1.25 g | 12 weeks | 15 |
| Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment 2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified | 800 mg | 2.4 g | 24 weeks | 15 |
| Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial 2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis | 120 mg | 1 g | 90 days | 15 |
| Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial 2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition | 260 mg | 2.4 g | 62 days | 12 |
| Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults 2020 · Fish oil group · Healthy physically active men and women aged 60–75 years | 1 g | 5 g | 12 weeks | 12 |
| Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions 2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition | 260 mg | 2.4 g | 62 days | 10 |
| Omega-3 fatty acids enhance the beneficial effect of BCAA supplementation on muscle function following eccentric contractions 2022 · BCAA+FO group · Healthy, untrained men aged 19–20 years | 260 mg | 2.4 g | 61 days | 10 |
| The effect of fish oil supplementation on resistance training-induced adaptations 2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease | 1.58 g | 4.5 g | 10 weeks | 10 |
| Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ 2000 · fish oil extract · Patients with distal proctocolitis; age and sex not reported | 2.4 g | — | 26 weeks | 9 |
| Distal procto-colitis, natural cytotoxicity, and essential fatty acids 1998 · fish oil extract · Patients with distal procto-colitis; age and sex not reported | 2.4 g | — | 26 weeks | 9 |
| Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors 2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training | 260 mg | 2.4 g | 62 days | 8 |
| Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes 2003 · n-3 PUFA diet · Elite athletes, including athletes with exercise-induced bronchoconstriction (EIB) and athletes without EIB; age and sex not reported | 2.2 g | 3.2 g | 3 weeks | 5 |
| Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults 2008 · Fish oil, no regular physical activity · Sedentary, overweight adults with risk factors for coronary disease | 1.56 g | 6 g | 12 weeks | — |
| Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults 2008 · Fish oil with regular physical activity · Sedentary, overweight adults with risk factors for coronary disease | 1.56 g | 6 g | 12 weeks | — |
| Fish oil supplementation improves neutrophil function during cancer chemotherapy 2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated | 400 mg | 2 g | 8 weeks | — |
| Effects of high-dose fish oil supplementation during early infancy on neurodevelopment and language: a randomised controlled trial 2012 · DHA-enriched fish oil group · Healthy term infants, from birth to 6 months | 250 mg | — | 26 weeks | — |
| Fish oil supplementation reduces cortisol basal levels and perceived stress: a randomized, placebo-controlled trial in abstinent alcoholics 2013 · fish-oil supplementation · Adult men with alcohol dependence undergoing residential rehabilitation | 252 mg | — | 3 weeks | — |
| Effect of Docosahexaenoic Acid (DHA) Supplementation of Preterm Infants on Growth, Body Composition, and Blood Pressure at 7-Years Corrected Age: Follow-Up of a Randomized Controlled Trial 2023 · high-DHA diet (intervention) · Preterm infants born before 33 weeks gestation and their breastfeeding mothers; enrolled within 5 days of commencing enteral feeds | 900 mg | 3 g | — | — |
| Omega-3 polyunsaturated fatty acids supplementation improves memory in first-diagnosed, drug-naïve patients with depression: Secondary analysis of data from a randomized controlled trial 2024 · n-3 PUFAs supplementation · Outpatients with first-diagnosed, drug-naïve depression receiving venlafaxine; age and sex not reported | 960 mg | 2.4 g | 12 weeks | — |
| Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study 1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported | 1.14 g | 1.71 g | 1 year | — |
| The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial 2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition | 400 mg | 2 g | 18 weeks | 134 |
| Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids 2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis | 480 mg | 2 g | 12 weeks | 40 |
| Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial 2022 · active group · Cognitively healthy adults aged 65 years and older | 430 mg | 1 g | 2 years | 30 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 400 mg | 2 g | 120 days | 26 |
| Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial 2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis | 1.8 g | 20 mL | 26 weeks | 24 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · EPA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 137 mg | — | 30 days | 22 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · DHA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 417 mg | — | 30 days | 22 |
| Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial 2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis | 1.8 g | 20 mL | 90 days | 20 |
| An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553] 2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress | 504 mg | 2 g | 6 weeks | 16 |
| Effects of dietary supplementation with a combination of fish oil, bilberry extract, and lutein on subjective symptoms of asthenopia in humans 2011 · Active group · People with subjective symptoms of asthenopia; age and sex not reported | 783 mg | — | 4 weeks | 11 |
| Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients 1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported | 140 mg | 216 mg | 6 weeks | — |
| Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial 2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms | 225 mg | 706 mg | 90 days | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.65 g | 3 g | 16 weeks | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.65 g | 3 g | 16 weeks | — |
| Fish oil amplifies the effect of propranolol in mild essential hypertension 1990 · Third subgroup: propranolol plus fish oil · Men with mild essential hypertension | 1.1 g | 9 g | 12 weeks | 16 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · FO concentrate · Obese men and women with BMI >30 | 1.2 g | 4 g | 12 weeks | 12 |
| The effects of supplemental fish oil on blood pressure and morning cortisol in normotensive adults: a pilot study 2012 · Fish Oil (FO) · Adults, mean age 35±13 years, normotensive | 800 mg | 4 g | 6 weeks | — |
| The effect of fish oil supplementation on serum phospholipid fatty acids profile during pregnancy: A double blind randomized controlled trial 2017 · Fish oil supplementation group · Pregnant women aged 18–35 years | 120 mg | 1 g | — | — |
| Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects 2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia | 3.7 g | 9.6 g | 4 weeks | 21 |
| The effects of low dose n-3 fatty acids on serum lipid profiles and insulin resistance of the elderly: a randomized controlled clinical trial 2010 · intervention group · Elderly Iranian residents aged 65 or older | 120 mg | 1 g | 26 weeks | — |
| A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults 2020 · SEDDS AquaCelle fish oil formulation · Healthy adults | 204 mg | 680 mg | 1 day | — |
| A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults 2020 · Unformulated fish oil EE control · Healthy adults | 204 mg | 680 mg | 1 day | — |
| A Randomized Double-Blinded, Placebo-Controlled Trial Investigating the Effect of Fish Oil Supplementation on Gene Expression Related to Insulin Action, Blood Lipids, and Inflammation in Gestational Diabetes Mellitus-Fish Oil Supplementation and Gestational Diabetes 2018 · omega-3 · Women aged 18–40 with gestational diabetes mellitus and no prior history of diabetes | 240 mg | 2 g | 6 weeks | 20 |
| Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y 2001 · Fish oil group · Healthy adults aged 55–75 years | 280 mg | 720 mg | 12 weeks | — |
| Sex, Body Mass Index, and APOE4 Increase Plasma Phospholipid-Eicosapentaenoic Acid Response During an ω-3 Fatty Acid Supplementation: A Secondary Analysis 2024 · ω-3 FA supplemented group · Healthy adults aged 20–80 years, men and women | 800 mg | — | 26 weeks | 92 |
| Maternal docosahexaenoic acid supplementation and fetal accretion 2003 · fish-oil capsules containing DHA · Pregnant mothers from 15 weeks gestation until term | 200 mg | — | — | 50 |
| Effect of docosahexaenoic acid-enriched fish oil supplementation in pregnant women with Type 2 diabetes on membrane fatty acids and fetal body composition--double-blinded randomized placebo-controlled trial 2014 · fish oil, women with Type 2 diabetes · Pregnant women with Type 2 diabetes | 600 mg | — | — | 41 |
| Predictors of change in omega-3 index with fish oil supplementation in peripheral artery disease 2017 · fish oil group · Adults with stable, mild or severe claudication due to peripheral arterial disease (Rutherford Class 1 to 3); primarily male, in their mid-sixties | 1.8 g | 4.4 g | 30 days | 40 |
| Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults 2025 · fish oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL | 820 mg | 1.16 g | 14 weeks | 20 |
| Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption 2016 · Lovaza ethyl ester condition · Healthy adults; age and sex not specified | 375 mg | 465 mg | 1 day | 18 |
| Dietary substitution with an alpha-linolenic acid-rich vegetable oil increases eicosapentaenoic acid concentrations in tissues 1994 · flaxseed group · Healthy adult men; age range not reported | 1.08 g | — | 8 weeks | 15 |
| Dietary substitution with an alpha-linolenic acid-rich vegetable oil increases eicosapentaenoic acid concentrations in tissues 1994 · control group · Healthy adult men; age range not reported | 1.08 g | — | 4 weeks | 15 |
| Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans 2004 · DHA · Healthy human subjects; age and sex not specified | 4.9 g | 4.9 g | 4 weeks | — |
| Long-chain n-3 polyunsaturated fatty acid dietary recommendations are moderately efficient in optimizing their status in healthy middle-aged subjects with low fish consumption: a cross-over study 2014 · commercial fish oil supplement · Healthy middle-aged adults with low customary fish consumption | 250 mg | — | 8 weeks | — |
| DHA-rich Fish Oil Increases the Omega-3 Index and Lowers the Oxygen Cost of Physiologically Stressful Cycling in Trained Individuals 2017 · DHA-rich tuna fish oil (FO) · trained males; age and health condition not specified | 560 mg | 560 mg | 8 weeks | — |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · ethyl ester (EE) · healthy normolipaemic men | 1.2 g | — | 7 weeks | — |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · triglyceride (TG) · healthy normolipaemic men | 1.4 g | — | 7 weeks | — |
| Prevention of Potential Adverse Metabolic Effects of a Supplementation with Omega-3 Fatty Acids Using a Genetic Score Approach 2020 · n-3 PUFA supplementation · Adults; age, sex, and health condition not specified | 1.1 g | 5 g | 6 weeks | 210 |
| Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease 2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes | 1.5 g | 3.36 g | 1 year | 147 |
| Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B₄ and leukotriene B₅ production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial 2014 · n-3 FA (active) · Adults aged 41–89 with colorectal cancer awaiting surgery | 1 g | — | 7 days | 74 |
| Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication | 1.8 g | 4.4 g | 30 days | 40 |
| DHA-enriched fish oil reduces insulin resistance in overweight and obese adults 2020 · FO (fish oil) intervention · Men and women with abdominal obesity, without diabetes; mean age 50.9 ± 12.7 years | 860 mg | 2 g | 12 weeks | 38 |
| Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations 2020 · Nutrient supplement phase, healthy participants · Healthy adults aged 20–65 years | 510 mg | — | 4 weeks | 27 |
| Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b 2013 · fish oil group · Adults aged 18–55 with relapsing-remitting multiple sclerosis, treated with interferon beta-1b | 1.6 g | 4 g | 1 year | 25 |
| Effects of oral supplementation with omega-3 fatty acids on nutritional state and inflammatory markers in maintenance hemodialysis patients 2014 · omega-3 group · Adults undergoing maintenance hemodialysis | 720 mg | — | 120 days | 25 |
| Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations 2020 · Nutrient supplement phase, participants with Crohn's disease · Adults aged 20–65 years with Crohn’s disease in remission | 510 mg | — | 6 weeks | 24 |
| Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome 2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m² | 1.45 g | 2.15 g | 6 weeks | 21 |
| Dietary supplementation with fish oil in ulcerative colitis 1992 · fish oil · Adults with active ulcerative colitis | 2.16 g | — | 120 days | 18 |
| DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men 2009 · DHA oil group · Men aged 39–66 with hypertriglyceridemia | 3 g | 7.5 g | 90 days | 17 |
| Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach 2014 · FO group · Healthy men and women aged 18–50 years | 900 mg | 8 g | 7 weeks | 17 |
| Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes 2000 · Fish oil · Postmenopausal women | 1.4 g | — | — | 15 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · High DHA-FO concentrate · Obese men and women with BMI >30 | 2 g | — | 12 weeks | 12 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 1.8 g | 4.4 g | 90 days | 11 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 1.8 g | 4.4 g | 90 days | 11 |
| Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer 1992 · fish oil group · Patients with sporadic adenomatous colorectal polyps; age and sex not reported | 3.6 g | — | 12 weeks | 10 |
| Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial 2012 · FO-N (normolipidemic fish oil group) · Men aged 29–51 years with normolipidemia | 1.14 g | 2.7 g | 12 weeks | 10 |
| Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition 2000 · fish oil extract · Patients with procto-colitis; age and sex not reported | 2.4 g | — | 26 weeks | 9 |
| Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial 2012 · FO-D (dyslipidemic fish oil group) · Men aged 29–51 years with dyslipidemia | 1.14 g | 2.7 g | 12 weeks | 9 |
| Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance 1991 · fish-oil supplementation · Obese adults with impaired glucose tolerance; mean age 50.3 years; sex not reported | 2.5 g | 30 mL | 2 weeks | 8 |
| Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects 1994 · fish oil · Subjects without cystic fibrosis; mean age 13.4 years | 2.2 g | 8 g | 6 weeks | 8 |
| Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects 1994 · fish oil · Patients with cystic fibrosis and pancreatic insufficiency; mean age 12.2 years | 2.2 g | 8 g | 6 weeks | 7 |
| Omega 3 Improves Both apoB100-containing Lipoprotein Turnover and their Sphingolipid Profile in Hypertriglyceridemia 2020 · n-3 supplementation · Six subjects with hypertriglyceridemia; age and sex not reported | 240 mg | 3 g | 60 days | 6 |
| Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics 1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract | 1 g | 4 g | 12 days | — |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · fish oil (FO) · Healthy subjects; age and sex not specified | 1.1 g | 9 g | 12 weeks | — |
| Moderate fish-oil supplementation reverses low-platelet, long-chain n-3 polyunsaturated fatty acid status and reduces plasma triacylglycerol concentrations in British Indo-Asians 2004 · Fish-oil group · British Indo-Asian Sikhs and Europeans; adults, age and weight matched between ethnic groups | 1 g | 4 g | 12 weeks | — |
| Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women 2008 · fish oil (FO) · pregnant women; age and health condition not specified | 500 mg | — | — | — |
| Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease 2009 · fish oil group · Patients with end-stage renal disease; age range and sex not reported | 600 mg | — | 26 weeks | — |
| ALOX5 gene variants affect eicosanoid production and response to fish oil supplementation 2011 · fish oil · African American adults aged 20–59 years, 68% female; no specific condition stated | 1 g | 5 g | — | — |
| [Effect on the lipid profile of diet supplemented with fish oil concentrate] 1990 · n-3 treated group · male and female patients with cholesterol values higher than 7.0 mmol/l | 1.5 g | 6 g | 12 weeks | — |
| Fish oil supplementation in early infancy modulates developing infant immune responses 2012 · fish oil group · Infants of high atopic risk, from birth; sex not specified | 280 mg | — | 26 weeks | — |
| Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults 2020 · EPA-rich fish oil · Healthy adults aged 23–44, without chronic or serious disease | 1.5 g | 12 g | 8 weeks | — |
| Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults 2020 · DHA-rich fish oil · Healthy adults aged 23–44, without chronic or serious disease | 3.6 g | 12 g | 8 weeks | — |
| The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial 2020 · fish oil + placebo · Overweight or obese pregnant women at increased risk for gestational diabetes | 1.9 g | 2.4 g | — | — |
| The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial 2020 · fish oil + probiotics · Overweight or obese pregnant women at increased risk for gestational diabetes | 1.9 g | 2.4 g | — | — |
| Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial 2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications | 800 mg | 3 g | 12 weeks | — |
| Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels 1996 · fish oil group · Healthy male university students | 950 mg | 4 g | 15 weeks | — |
| A Mixed Flavonoid-Fish Oil Supplement Induces Immune-Enhancing and Anti-Inflammatory Transcriptomic Changes in Adult Obese and Overweight Women-A Randomized Controlled Trial 2016 · Q-Mix · Women aged 40–70 years who were overweight or obese (BMI ≥25 kg/m²), without the listed major diseases | 90 mg | 200 mg | 10 weeks | 24 |
| The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial 2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program | 1.2 g | 6 g | 4 weeks | 11 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 200 mg | 1.05 g | — | 10 |
| A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone 2021 · risperidone + FO · Patients aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum disorders or bipolar disorder | 400 mg | — | 16 weeks | 10 |
| Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye 2011 · omega-3 group · Patients with dry eye; age and sex not reported | 300 mg | — | 90 days | — |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 120 mg | 180 mg | 4 weeks | — |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 800 mg | 3 years | 401 |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 800 mg | 3 years | 399 |
| Effect of docosahexaenoic acid-enriched fish oil supplementation in pregnant women with Type 2 diabetes on membrane fatty acids and fetal body composition--double-blinded randomized placebo-controlled trial 2014 · fish oil, healthy women · Healthy pregnant women | 600 mg | — | — | 45 |
| Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women 2008 · fish oil (FO) and methyl-tetra-hydrofolic acid · pregnant women; age and health condition not specified | 500 mg | — | — | — |